the strategy for patient-oriented research (spor) is a national coalition of federal, provincial and territorial partners (patients and informal caregivers, health authorities, academic health centres, charities, philanthropic organizations, private sector, etc.) dedicated to the integration of research into care.

patient-oriented research, which is foundational to evidence-informed health care, refers to a continuum of research that engages patients as partners, focusses on patient-identified priorities and improves patient outcomes. this research, conducted by multidisciplinary teams in partnership with relevant stakeholders, aims to apply the knowledge generated to improve healthcare systems and practices.

the vision for spor is that canada will demonstrably improve health outcomes and enhance the health care experience for patients through the integration of evidence at all levels of the health care system.

innovative clinical trials initiative

the spor innovative clinical trials (ict) initiative contributes to increasing canadian competitiveness in ict research and provides a stimulus for trialists to adopt new methodologies, enhance patient and clinician engagement in research, and build capacity and increase the intensity of ict research. icts use non-traditional designs that are alternative to traditional randomized controlled trials (rcts), with application in areas ranging from product development to health system improvement. ict methods reduce the cost of conducting trials, reduce the amount of time needed to answer research questions, and increase the relevance of research findings to patients, healthcare providers and/or policy makers. adopting these alternative designs can maximize the use of existing knowledge and data.

research areas

spor icts need to have a primary focus in the research areas of:

comparative effectiveness research:

comparative effectiveness research compares two or more healthcare options already shown to be efficacious. the healthcare options could include diagnostics, drugs, medical devices, surgeries, complementary medicine, self-care or ways to deliver health care. the findings should be able to inform healthcare decisions by providing evidence on the effectiveness, benefits, and harms of different healthcare options and other types of interventions; and/or

implementation science research: implementation science research examines interventions that are already shown to work under certain conditions and within certain contexts, which could be defined by demographic, biological, clinical, social, economic, geographic, or other factors. the interventions could include diagnostics, drugs, medical devices, surgeries, complementary medicine, self-care or ways to deliver health care. implementation science aims to determine if these interventions can be adapted to other contexts, how should they be adapted and what are the longer term effects.  in other words, implementation research seeks to understand what interventions work for whom and under what circumstances. it studies the factors that influence the full and effective use of interventions in practice, which could include affordability, adaptability, sustainability and equitable scalability.

application requirements

to meet the requirements of the funding opportunity, the following elements must be included as part of an application:

• the proposed research activities must be patient-oriented in that:
  • patients are engaged as partners;
  • there is a focus on patients’ priorities;
  • the aim is to improve patient outcomes;
  • the work is conducted by a multi-disciplinary team that includes patients;
  • there is involvement of other spor stakeholders such as policy makers, health care professionals and health charities; and
  • research findings can be applied to health care or policy.
• the proposed research must be an ict as described above.
• applicants must focus on comparative effectiveness research and/or implementation science research as described above.
• applicants are required to explore collaborations with the spor support units, the spor canadian data platform, and the spor evidence alliance to strengthen their application and support the research project.

this funding opportunity is expected to:

• support the creation and/or further development of formal networks by encouraging national and international collaboration, resource sharing, capacity building and dissemination in priority research areas;
• identify and establish novel connections across canada. this will bring together a collaborative multidisciplinary group of technical and scientific experts;
• develop and strengthen research capacity by connecting and engaging current researchers and training the next generation of researchers;
• develop and provide health research leadership across canada, linking to related international initiatives (as appropriate);
• facilitate translation of new knowledge generated by research evidence; and
• ensure patient engagement to increase the outcomes and health impacts for canadians.

the joseph and wolf lebovic cancer genomics and immunity fellowship program aims to support projects that will uncover the diverse interactions between tumour and immune cells, for the development of new therapeutic strategies. the program aims to harness the power of genomic analytic tools with that of diverse animal and cellular experimental systems, through collaborative work between the ontario institute for cancer research (oicr) and the institute for medical research israel-canada (imric) scientists. imric an institute of the hebrew university.

scope

• the program will provide support for trainees – 世界杯2022赛程表淘汰赛 /postdoctoral fellows – working on joint projects between imric and ontario-based scientists addressing the interactions between cancer and immune cells;
• two projects will be selected to receive support over a two-year period;
• each collaborative project will support two trainees, one from each institution; and
• each project will be funded at $80,000 cad per year divided equally between the two institutions ($40,000 cad per institution per year).

partnership engage grants are expected to respond to the objectives of the insight program and the connection program. please note that partnership engage grants cannot respond exclusively to the objectives of the connection program.

these grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. the small-scale, stakeholder-driven partnerships supported through partnership engage grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors. in addressing an organization-specific need, challenge and/or opportunity, these partnerships let non-academic organizations and postsecondary researchers access each other’s unique knowledge, expertise and capabilities on topics of mutual interest.

sshrc welcomes applications involving indigenous research, as well as those involving research-creation.

the three canadian federal research funding agencies and uk research and innovation(ukri) are pleased to announce their intention to launch the canada-uk artificial intelligence initiative. 

the canadian agencies include the canadian institutes of health research (cihr); the natural sciences and engineering research council (nserc); and the social sciences and humanities research council (sshrc). the four uk research councils involved in this ukri initiative are the arts and humanities research council (ahrc); the economic and social research council (esrc); the engineering and physical sciences research council (epsrc); and the medical research council (mrc). esrc is coordinating this initiative. 

the rapid development and ever-growing global investment in artificial intelligence (ai) illustrate the undeniable impact that these technologies are having, and will have, on our economies, health and societies. given the expertise of researchers in canada and the united kingdom, the canadian agencies and ukri are jointly supporting the development of a collaboration in ai among stakeholders in canada and the uk aimed at building competitive and resilient economies and maximizing the social and health benefits. the aim is to build competitive and resilient economies and maximize the social and health benefits.

this is a unique collaboration which will require each project to include a principal investigator (pi) based in canada and a pi based in the uk who will share equally leadership and project management responsibilities. the canadian and uk applicants will develop a common research plan and jointly prepare the full proposal. proposals will be required to demonstrate a significant degree of, or novel approach to, interdisciplinarity, with research that cuts across at least two of the following research domains: social sciences and humanities; health and biomedical sciences; and natural sciences and engineering (including computational and/or mathematical sciences).  

in addition to promoting interdisciplinary ai, this call will support the development of responsible ai while establishing new partnerships and enhancing infrastructure and training between researchers in canada and the uk. the outputs and outcomes of the research should allow for uptake by relevant stakeholders where possible.

the fy19 defense appropriation provides $20 million (m) to the department of defense joint program committee 8/clinical and rehabilitative medicine research program (jpc-8/crmrp) to support the development of regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damage due to traumatic injury through collaborative partnerships and synergistic projects that inform and build on each other.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the jpc-8/crmrp is offering the regenerative medicine focused research award (rmfra) as its next iteration of the armed forces institute of regenerative medicine (afirm), afirm iii, in fy19 to continue its effort to support the development of regenerative medicine solutions.  the fy19 jpc-8/crmrp program announcement and general application instructions for the rmrfa mechanism are posted on the grants.gov website. 

focus areas and areas of encouragement

all projects submitted under the fy19 jpc-8/crmrp rmfra will be required to address one or both of the following focus areas:

• ·         peripheral nerve regeneration
• ·         skeletal muscle regeneration

efforts to regenerate peripheral nerve should focus on restoring maximal function; the goal should be accelerating functional recovery and/or reducing the need for autograft; efforts should not simply address metrics of nerve regrowth or conduits to cross nerve gaps.  similarly efforts to regenerate skeletal muscle should extend beyond restoration of muscle bulk or structure and address restoration of maximal muscle function.  the fy19 jpc-8/crmrp rmfra areas of encouragement include:

• ·         immediate reconnection of severed peripheral nerves (e.g., preventing wallerian degeneration)
• ·         regeneration of composite muscle and nerve injuries leading to improved function
• ·         regenerative therapies for volumetric muscle loss
• ·         preservation of denervated end organs
• ·         maintenance of the motor end plate or regeneration of the neuromuscular junction
• ·         improving the rate of peripheral nerve regeneration

https://cdmrp.army.mil/funding/jpc8

regenerative medicine focused research award (rmfra) – preproposal due august 7, 2019

independent investigators at all academic levels (or equivalent)

• ·        preproposal is required; full application submission is by invitation only.
• ·        accommodates either single principal investigator (pi) or multiple pi submissions.  all research teams should include highly qualified investigators. partnerships should include multidisciplinary investigators that bring resources and expertise that combine to create a robust, synergistic collaboration.
• ·        supports the development of regenerative medicine technical capabilities and solutions through collaborative partnerships and synergistic projects (multiple pi submissions) or through comprehensive projects (single pi submissions) to accelerate regenerative medicine solutions and technical capabilities that repair, reconstruct, or regenerate tissue lost or damaged due to traumatic injury
• ·        multi-institutional collaborations between/among academia, industry, and department of defense and/or department of veterans affairs facilities are highly encouraged.
• ·        research projects should be either advanced preclinical research or early stage clinical trials (phase 0, i, or iia)
• ·        applications must address one or both of the fy19 joint program committee 8/crmrp rmfra focus areas
• ·      maximum funding of $10 million (m) for total costs (direct plus indirect costs).
• ·      submissions may range in size and scope as appropriate for the work proposed, and will be equally considered.  submissions with a total of less than the maximum  of $10m are encouraged
• ·      maximum period of performance is 5 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcement and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the jpc-8/crmrp, please visit the crmrp website (https://crmrp.amedd.army.mil).

point of contact:

cdmrp help desk 
301-682-5507
help@ebrap.org

the fy19 defense appropriation provides $20 million (m) to the department of defense kidney cancer research program (kcrp) to support research of exceptional scientific merit in the area of kidney cancer.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 kcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

https://cdmrp.army.mil/funding/kcrp

academy of kidney cancer investigators - dean award – letter of intent due september 17, 2019

dean must be an established kidney cancer researcher.

• ·       supports visionary individuals who are established kidney cancer researchers with a strong record of mentoring and commitment to leadership.
• ·       academy dean will oversee an interactive virtual academy of early-career investigators and their designated mentors, facilitate regular interactive communication among all academy members, and assess the research progress and career progression of the early-career investigators.
  • ·      maximum funding of $625,000 for direct costs (plus indirect costs).
• ·       maximum period of performance 5 years.
• ·       indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

academy of kidney cancer investigators - early career investigator award – letter of intent due september 17, 2019

must be within 3 years of his/her last postdoctoral research position (ph.d.) or clinical fellowship (m.d.), or equivalent as of full application submission deadline.

letter attesting to eligibility required.

• ·       supports addition of new early-career investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.
• ·       early-career investigators whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• ·       a designated mentor who is an experienced kidney cancer researcher with kidney cancer funding is required.
• ·       the designated mentor not required to be at the same institution as the early-career investigator.
• ·       preliminary data required.
• ·       clinical trials are not allowed.
  • ·      maximum funding of $725,000 for direct costs (plus indirect costs).
• ·       maximum period of performance 4 years.
• ·       indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

clinical consortia award – letter of intent due september 17, 2019

independent investigators at or above the level of assistant professor (or equivalent)

• ·       supports development of a consortium that will facilitate rapid execution of collaborative clinical trials that will bring to market high-impact, novel therapeutics that will ultimately and significantly decrease the impact of kidney cancer.
• ·       funds may not be used for research or development of clinical protocols.
• ·       trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer encouraged.
• ·       one coordinating center and three clinical trial sites will be selected and be jointly responsible for proposing, selecting, and conducting trials.
• ·       sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer
• ·       consortium expected to achieve financial self-sufficiency, such that operations can continue after the award ends.
• ·       the consortium is expected to achieve financial self-sufficiency, such that operations can continue after the award period ends.

coordinating center:

• ·       maximum funding of $3m for direct costs (plus indirect costs).
  • ·      maximum period of performance is 3 years.
  • ·      indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

clinical trial sites:

• ·      maximum funding of $600,000 for direct costs (plus indirect costs).
• ·       maximum period of performance is 3 years.
• ·       indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the kcrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org